Candel Therapeutics, Inc.

Candel Therapeutics, Inc. reported a net loss of $38.9 million for the second quarter of 2026, with a diluted EPS of $(0.52). For the first six months of 2026, the company's net loss was $47.8 million, a significant increase from a net income of $2.6 million in the same period last year. Despite the losses, the company substantially strengthened its cash position, raising $93.5 million net from a public offering and an additional $24.2 million net through at-the-market offerings, bringing total cash and cash equivalents to $201.6 million as of June 30, 2026.

Candel Therapeutics announced its second quarter 2026 financial results, reporting a net loss of $38.9 million and increased R&D and G&A expenses. The company plans to submit a Biologics License Application (BLA) for aglatimagene in localized prostate cancer in Q4 2026, following positive phase 3 data published in The Lancet Oncology. Candel also activated the first site for its pivotal phase 3 AURORA trial for aglatimagene in NSCLC and appointed a Chief Commercial Officer. With $201.6 million in cash and cash equivalents, the company expects to fund operations into Q1 2028.

Candel Therapeutics reported a net loss of $38.9 million for Q2 2026, significantly higher than the $4.8 million loss in Q2 2025, primarily due to increased R&D and commercial readiness costs. Despite the increased loss, the company announced plans to submit a Biologics License Application (BLA) for aglatimagene in localized prostate cancer in Q4 2026 and activated the first site for its pivotal phase 3 AURORA trial in NSCLC. Candel also strengthened its commercial team with a new Chief Commercial Officer and reported $201.6 million in cash and cash equivalents, sufficient to fund operations into Q1 2028.

Candel Therapeutics, Inc. announced that its Compensation Committee granted inducement stock options to three new employees on July 31, 2026. These options allow the purchase of an aggregate of 30,800 shares of the company's common stock at an exercise price of $10.01 per share. The awards, made under the 2025 Inducement Plan, vest 25% after one year and the remaining 75% over 36 equal monthly installments, subject to continued employment.

Candel Therapeutics, Inc. announced that an abstract detailing its aglatimagene besadenovec immunotherapy for localized prostate cancer has been accepted for a poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The presentation will take place on September 29, 2026. This highlights the company's progress in developing multimodal immunotherapies for cancer, with aglatimagene besadenovec already holding FDA Fast Track and RMAT designations.

Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced it will present at Canaccord Genuity's 46th Annual Growth Conference. The presentation is scheduled for August 12, 2026, at 12 PM EDT. A webcast of the presentation will be accessible via the company's investor relations website, with a replay available for 90 days. The company focuses on developing multimodal immunotherapies for cancer.

Candel Therapeutics, Inc. announced the appointment of Mark Sims as its new Chief Commercial Officer, effective July 6, 2026. In connection with his employment, the Compensation Committee granted Mr. Sims inducement stock options to purchase an aggregate of 285,000 shares of common stock. The options have an exercise price of $10.03 per share and will vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.

Candel Therapeutics announced that its Compensation Committee granted stock options to one new employee on June 30, 2026. The grant includes options to purchase an aggregate of 25,000 shares of common stock at an exercise price of $10.30 per share. These inducement awards, made under the Company's 2025 Inducement Plan, vest 25% on the first anniversary and the remaining 75% in 36 equal monthly installments, subject to continued employment. Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies for cancer.

Candel Therapeutics announced the initiation of its global pivotal Phase 3 AURORA trial for aglatimagene besadenovec (CAN-2409) in combination with valacyclovir and continued pembrolizumab. This trial targets patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease has progressed despite prior immune checkpoint inhibitor and platinum-based chemotherapy. The study, which has its first site open for enrollment, will compare this regimen against standard-of-care docetaxel chemotherapy, with overall survival as the primary endpoint. The FDA previously granted Fast Track Designation to aglatimagene for NSCLC, and Candel has partnered with Parexel International for trial execution.

Candel Therapeutics, Inc. announced the appointment of Mark Sims as Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead the commercial strategy and launch readiness for aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer. This appointment supports the planned BLA submission in Q4 2026 and a potential 2027 launch, targeting approximately 65,000 US patients annually. Mr. Sims brings over 25 years of oncology commercial experience to the role.